应用于眼部治疗的纳米技术药物研究进展  

Research Advances in Nanotechnology Drugs for the Treatment of Eye Diseases

作　　者：李则青 袁松涛[2] 徐寒梅[1] 胡加亮[1] 薛建鹏[1] LI Zeqing;YUAN Songtao;XU Hanmei;HU Jialiang;XUE Jianpeng(Engineering Research Center of Synthetic Polypeptide Drug Discovery and Evaluation of Jiangsu Province,China Pharmaceutical University,Nanjing 211198,China;Department of Ophthalmology,The First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China)

机构地区：[1]中国药科大学江苏省合成多肽药物发现与评价工程中心,江苏南京211198 [2]南京医科大学第一附属医院眼科,江苏南京210029

出　　处：《药学进展》2020年第6期459-465,共7页Progress in Pharmaceutical Sciences

基　　金：江苏省自然科学基金青年资助项目(No.BK20160757);中国药科大学“双一流”新药研发建设项目(No.CPU2018PZH03,No.2017ZX09101002-002-003)。

摘　　要：眼睛中复杂的给药屏障使许多药物在眼部的生物利用度降低,治疗效果较差。已有研究表明,纳米载体介导的药物可与眼部黏膜相互作用,延长药物在眼部的保留时间并增加渗透性;纳米胶束、纳米粒、脂质体、纳米乳等新型纳米给药载体具有用于眼部给药的发展潜力。综述近年来眼部给药屏障、给药途径及新型纳米载体药物等方面的研究进展,以期为相关药物研发及临床治疗提供参考。The complex drug delivery barrier leads to poor bioavailability and poor therapeutic effects of drugs for the treatment of problems with eyes.Studies have shown that nanocarrier-mediated drugs interact with the ocular mucosa,prolonging the retention time of the drug in the eye and increasing permeability.Novel drug carriers such as nanomicelles,nanoparticles,liposomes and nanoemulsions have the potential for ocular administration.This article reviews the recent research progress in ophthalmic drug delivery barriers,drug delivery routes and novel nanocarrier drugs,in order to provide reference for the development and clinical application of related drugs.

关 键 词：眼部给药系统 眼部屏障 纳米载体 眼部疾病 

分 类 号：R988.1[医药卫生—药品]